NuVasive logo
NuVasive NUVA

Quarterly report 2023-Q2
added 08-02-2023

report update icon

NuVasive Financial Statements 2011-2025 | NUVA

Annual Financial Statements NuVasive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.29 B 2.68 B 2.76 B 4.09 B 2.5 B 2.54 B 3.49 B 2.25 B 2.16 B 1.69 B 751 M 630 M

Shares

52 M 51.6 M 51.4 M 52 M 51.4 M 50.9 M 50.1 M 48.7 M 46.7 M 44.5 M 43.3 M 40.4 M

Historical Prices

44.1 52 53.7 77.1 50.1 48.9 70.8 46.1 46.3 37.4 17.2 15.5

Net Income

40.4 M -64.1 M -37.2 M 65.2 M 12.5 M 83 M 37.1 M 66.3 M -16.7 M 7.9 M 3.14 M -69.8 M

Revenue

1.2 B 1.14 B 1.05 B 1.17 B 1.1 B 1.03 B 962 M 811 M 762 M 685 M 620 M 541 M

Cost of Revenue

337 M 322 M 322 M 312 M 311 M 268 M 240 M - - - - -

Gross Profit

865 M 817 M 729 M 856 M 791 M 761 M 722 M 617 M 580 M 505 M 467 M 428 M

Interest Expense

-21.4 M -25.5 M -16.9 M -5.92 M -8.17 M -1.54 M -305 K 425 K -2.41 M 3.1 M 1.05 M 2.08 M

EBITDA

147 M 150 M 141 M 172 M 153 M 170 M 140 M 116 M 72.4 M 52.4 M 59.1 M 40.9 M

Operating Expenses

777 M 829 M 691 M 735 M 688 M 638 M 624 M 513 M 521 M 472 M 420 M 394 M

General and Administrative Expenses

634 M 610 M 547 M 611 M 576 M 540 M 534 M 465 M 470 M 420 M 372 M 347 M

All numbers in USD currency

Quarterly Income Statement NuVasive

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

52.4 M 52.2 M 52.1 M 52.1 M 52 M 51.8 M 51.8 M 51.7 M 51.6 M 51.4 M 51.4 M 51.3 M 51.2 M 51.8 M 52.1 M 52.1 M 52 M 51.7 M 56.6 M 51.4 M 51.4 M 51.2 M 56.2 M 50.7 M 51.1 M 50.6 M 55.2 M 50.3 M 50 M 49.6 M 52.6 M 49 M 48.5 M 48 M 47.7 M 47 M 46.8 M 45.8 K 44.9 M 44.6 M 44.4 M 44 M 43.7 M 43.5 M 43.3 M 42.8 M 42.5 M 39.9 M 39.8 M 39.6 M

Net Income

7.36 M -1.01 M - -1.98 M -893 K 19.2 M - -21.6 M 1.8 M -7.51 M - 5.87 M -50 M 5.3 M 29.9 M 11 M 15 M 9.39 M 12.2 M 15.9 M 11.5 M -27.1 M 23.5 M 33.5 M 12.2 M 12.4 M 6.38 M 3.93 M 30.2 M -3.37 M 11.5 M 13 M 10.3 M 31.6 M 7.47 M -1.83 M -4.09 M -18.3 M 6.01 M 7.51 M -6.47 M 851 K -2.75 M 2.35 M 2.86 M 673 K -10 M -67.6 M 5.38 M 2.36 M

Revenue

318 M 308 M - 295 M 310 M 291 M - 271 M 295 M 271 M - 295 M 204 M 260 M 310 M 291 M 292 M 275 M 288 M 271 M 282 M 261 M 271 M 247 M 259 M 249 M - - - - - - - - - - - - 191 M 169 M 166 M 160 M 166 M 148 M 154 M 152 M - - - -

Cost of Revenue

89.5 M 86.4 M - 80.9 M 85.8 M 79.1 M - 88.7 M 78.3 M 71.8 M - 84.6 M 80.5 M 71.9 M - 77 M 77.6 M 74.5 M - 74.2 M 77.1 M 73.8 M - 65.5 M 66.2 M 61.4 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

228 M 221 M - 214 M 225 M 212 M - 182 M 217 M 199 M - 211 M 123 M 188 M 227 M 214 M 215 M 200 M 202 M 197 M 205 M 187 M 196 M 182 M 193 M 188 M 204 M 180 M 176 M 161 M 164 M 151 M 154 M 147 M 158 M 142 M 146 M 134 M 141 M 126 M 117 M 120 M 124 M 111 M 118 M 115 M 113 M 107 M 107 M 101 M

Interest Expense

-826 K -4.44 M - -21.1 M -29.7 M 16.2 M - -13.1 M 1.27 M -12.5 M - 251 K -11.7 M -7.41 M - -5.7 M 9 K -366 K - 4.24 M -2.38 M -9.7 M - -139 K -501 K 258 K - 94 K -246 K 50 K - 387 K -281 K 424 K - -2.49 M -205 K 375 K - 3.14 M -440 K 240 K - 260 K -551 K 437 K - 1.73 M 80 K 497 K

EBITDA

8 M 33.5 M - 110 M 13.4 M 36.8 M - 112 M 15.9 M 36.4 M - 106 M 70.1 M 35 M - 101 M 67.6 M 34.1 M - 96.4 M 64.2 M 32.1 M - 88.9 M 58.7 M 29.5 M - 73.8 M 46.3 M 21.2 M - 49 M 32.6 M 16.1 M - 46.5 M 31 M 15.4 M - 46.3 M 30.3 M 14.6 M - 38.2 M 25.3 M 12.1 M - 24.8 M 15.9 M 7.78 M

Operating Expenses

210 M 214 M - 193 M 192 M 200 M - 189 M 206 M 187 M - 184 M 160 M 160 M - 183 M 184 M 180 M - 179 M 176 M 205 M - 151 M 164 M 165 M - 159 M 116 M 149 M - 123 M 129 M 91.2 M - 126 M 141 M 162 M - 114 M 117 M 114 M - 98.1 M 105 M 108 M - 198 M 96 M 96.3 M

General and Administrative Expenses

164 M 176 M - 154 M 161 M 160 M - 146 M 157 M 146 M - 146 M 126 M 130 M - 153 M 153 M 145 M - 141 M 146 M 147 M - 126 M 139 M 140 M - 132 M 134 M 125 M - 111 M 115 M 116 M - 114 M 117 M 118 M - 102 M 104 M 99.9 M - 87.4 M 92.6 M 94.7 M - 85.5 M 84.3 M 84.2 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements NuVasive NUVA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting NuVasive plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.86 -3.26 % $ 134 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 307.92 -1.93 % $ 8.69 B usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 45.13 -2.67 % $ 6.72 K usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 125.1 1.48 % $ 218 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 92.34 0.64 % $ 136 B usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 2.56 8.94 % $ 95.5 M franceFrance
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.92 -4.72 % $ 14.8 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 96.35 -1.06 % $ 1.22 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 17.7 -3.46 % $ 408 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
LivaNova PLC LivaNova PLC
LIVN
$ 62.79 -1.82 % $ 3.41 B britainBritain
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 2.53 0.86 % $ 99 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 14.56 0.76 % $ 1.15 B israelIsrael
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 9.88 0.05 % $ 709 M israelIsrael
Myomo Myomo
MYO
$ 1.06 -1.85 % $ 7.47 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 13.41 -4.56 % $ 1.03 B usaUSA
Align Technology Align Technology
ALGN
$ 165.15 0.78 % $ 12.4 B usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 1.07 -3.18 % $ 110 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 12.81 -1.23 % $ 346 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 15.51 -1.27 % $ 591 M curacaoCuracao
FONAR Corporation FONAR Corporation
FONR
$ 14.86 -0.03 % $ 97.4 M usaUSA
AxoGen AxoGen
AXGN
$ 30.33 1.15 % $ 1.34 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 40.78 2.33 % $ 1.26 B usaUSA
LENSAR LENSAR
LNSR
$ 11.48 -0.17 % $ 132 M usaUSA